Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects Podcast (2023)

Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA is offering phase two of an educational series to update urologists and advanced practice providers (APPs) on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. Part II will consist of two live webinars, one designed specifically for urologists and the other for APPs. The live virtual courses will feature a multidisciplinary panel engaging in a lively discussion on this topic. For a deeper dive into select topics in ADT and advanced prostate cancer care, the AUA will also produce two additional episodes for release on the AUAUniversity Podcast:

Systemic Therapies for Advanced Prostate Cancer – Short and Long-Term Side Effects Podcast (2023)

 

ACKNOWLEDGEMENTS:

This series is supported by independent educational grants from: 

Myovant Sciences LTD
Pfizer, Inc.

Target Audience

  • Urologists
  • Advanced Practice Providers (APPs)

Learning Objectives

At the conclusion of these activities, participants will be able to:

  1. Characterize current treatment paradigm for systemic therapies in managing advanced prostate cancer including doublet and triple therapy.
  2. Identify short and long-term side effects of ADT and novel hormonal treatments for advanced prostate cancer including cardiovascular, bone health, and metabolic risk.
  3. Recognize strategies to monitor and manage side effects of ADT and novel hormonal treatments.
  4. Understand adverse effects of newer agents for advanced prostate cancer including PARP inhibitors, immunotherapy, and theranostics.
  5. Review management options for adverse effects of newer agents for advanced prostate cancer.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Course opens: 
10/18/2023
Course expires: 
10/18/2024
Rating: 
0

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures


AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Moderator(s)

Jay Raman, MD, FACS

has no relevant financial relationships to disclose at this time.
Podcast Co-Host(s)

Chad Ritch, MD, MBA

has a financial relationship (Consultant or Advisor (Oncology)) with mIR Scientific;.
has a financial relationship (Consultant or Advisor (Oncology)) with Nonagen Inc;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by listening to the podcast and completing the post-test and evaluation. To claim CME credit for this enduring material, learners must complete the post-test, passing with 80% accuracy, and submit the program evaluation.

Estimated time to complete this activity: 0.50 hours

Release Date: October, 2023
Expiration Date: October, 2024

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

MITIGATION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Non-Physician Participation
Please login or register to take this course.